Latest
The latest peptide research news, clinical trial results, and industry updates from trusted sources.
861 articles
Saitama University researchers discover that a natural peptide aptamer switches between two target proteins depending on metal ions EurekAlert!
The STRIDE Trial and Semaglutide: Implications for Clinical Vascular Practice. Ravindhran B(1), Chetter I(1), Pymer S(2). Author information: (1)Academic Vascular Surgical Unit, Hull York Medical School, University of Hull / Hull University Teaching Hospitals NHS Trust, Hull, UK. (2)Academic Vascular Surgical Unit, Hull Your Medical School, University of Hull / Hull University Teaching Hospitals NHS Trust, Hull, UK. Electronic address: s.pymer@nhs.net.
Structure-Based Adaptation of a SARS-CoV-2 Neutralizing Peptide to New Virus Variants. Raasch N(1), Weißenborn L(1), Richel E(2), Schäfer S(3), Denysenko O(3), Bartelsen N(2), Sticht H(3), Überla K(2), Eichler J(1). Author information: (1)Department of Chemistry and Pharmacy, Medicinal Chemistry, FAU NeW - Research Center New Bioactive Compounds, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen 91058, Germany. (2)Harald zur Hausen Institute of Virology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen 91054, Germany. (3)Institute of Biochemistry, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen 91054, Germany. The starting point of this work was a SARS-CoV-2 neutralizing peptide (LW25.13), which binds to the receptor-binding domain of the viral spike protein and inhibits the attachment of the virus to its cellular receptor ACE2. As LW25.13 is unable to neutralize later SARS-CoV-2 variants, such as omicron, we have extended the neutralization breadth of LW25.13 through structural and bioinformatic analysis. This involved the systematic variation of a range of positions and yielded peptides neutralizing SARS-CoV-2 beta and omicron at low nanomolar concentrations, while preserving the strong neutralizing capacity against earlier virus variants (wild-type, alpha, delta), as well as the proteolytic stability and α-helical conformation of the peptide. This gain in neutralizing breadth illustrates the utility of the peptide as a scaffold that can be adapted to different virus variants, which may prove useful for the development of peptides against new coronavirus variants of concern in the future.
Combining an α(v)β(6)-Targeted (177)Lu-Based Peptide Receptor Radionuclide Therapy with Olaparib to Boost Therapeutic Efficacy in Pancreatic Cancer. Ganguly T(1), Harris RE(2), Hausner SH(2), Sutcliffe JL(3)(2)(4). Author information: (1)Department Biomedical Engineering, University of California Davis, Davis, California. (2)Division of Hematology/Oncology, Department of Internal Medicine, University of California Davis, Sacramento, California; and. (3)Department Biomedical Engineering, University of California Davis, Davis, California; jlsutcliffe@health.ucdavis.edu. (4)Center for Molecular and Genomic Imaging, University of California Davis, Davis, California. Pancreatic ductal adenocarcinoma is one of the most lethal malignances worldwide, and there remains an urgent need for more effective and less toxic treatment strategies. Integrin αvβ6 is a cell-surface receptor that is overexpressed in several malignancies, including pancreatic ductal adenocarcinoma, and plays a key role in invasion and metastasis, making it a promising molecular target for the detection and treatment of many cancers. We investigated a molecularly targeted approach that exploits the overexpression of αvβ6 using peptide receptor radionuclide therapy (PRRT) in combination with the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib. Methods: We combined the αvβ6-targeted PRRT agent [177Lu]Lu-DOTA-ABM-5G with olaparib, a PARP inhibitor. The combination therapy was evaluated in vitro in αvβ6-positive pancreatic Capan-1 cells by investigating its effect on cell viability, apoptosis induction, cell cycle arrest, and the formation of double-strand breaks. In vivo pharmacokinetic and therapeutic efficacy studies were performed in mice bearing Capan-1 xenograft tumors. Results: In vitro, the [177Lu]Lu-DOTA-ABM-5G was rapidly internalized by αvβ6-positive pancreatic Capan-1 cells; in vivo, it was taken up by Capan-1 xenograft tumors in mice. Combination treatment with [177Lu]Lu-DOTA-ABM-5G and olaparib significantly reduced cell viability (water-soluble tetrazolium salt 1 assay), significantly increased the percentage of cells in the sub-G1 and G2/M phases (cell cycle analysis), and resulted in the greatest number of γ-H2AX foci per cell compared with single-agent treatment. In vivo, the combination treatment delayed tumor growth progression and significantly improved median survival compared with the control and single-agent treatments, with no observed treatment-related adverse events. Conclusion: The combination of αvβ6-targeted PRRT and PARP inhibition enhanced therapeutic efficacy compared with single-agent treatment. These findings warrant further investigation, particularly given the urgent need for improved treatments for pancreatic cancer. © 2026 by the Society of Nuclear Medicine and Molecular Imaging.
Orofacial adverse events associated with Glucagon-like peptide-1 receptor agonists: a real-world multinational retrospective matched cohort study. Oyewole SO(1), Owosho AA(2). Author information: (1)College of Medicine, University of Cincinnati, Cincinnati, OH, USA. (2)The Robert Ebert and Greg Stubblefield Head and Neck Tumor Center, Barnes-Jewish Hospital and Washington University School of Medicine, St. Louis, MO, USA; Oral Medicine, Dental Oncology and Urgent Care Unit, Missouri School of Dentistry and Oral Health, A.T. Still University, Kirksville, MO, USA. Electronic address: adepitanowosho@atsu.edu. BACKGROUND: This study quantifies orofacial adverse event risks associated with Glucagon‑like peptide‑1 receptor agonists (GLP-1RAs), addressing public concerns like "Ozempic teeth/mouth/tongue" Using a large-scale matched cohort, it clarifies associations between GLP-1RA therapy and oral health. MATERIALS AND METHODS: We performed a retrospective cohort analysis within the TriNetX research network, comparing GLP‑1RA users with age‑ and sex‑matched controls in a 1:1 propensity‑matched design. Individuals with prior orofacial conditions or predisposing therapies to adverse outcomes were excluded. ICD-10 codes identified orofacial adverse outcomes across mucosal, salivary, neuropathic, and dental categories. Odds ratio (OR) and 95% confidence intervals were calculated to assess orofacial adverse event risks. RESULT: A cohort of 226,485 GLP‑1RA users was analyzed after exclusions and matching. Gastroesophageal reflux disease (GERD) (5.36%) was the most frequent event, while most conditions were rare. Compared with controls, GLP‑1RA therapy did not increase risk for most outcomes and showed significant inverse associations for multiple mucosal, neuropathic, salivary, and dental conditions (OR = 0.893-0.295). Only GERD (OR = 1.329 [1.291-1.367]) demonstrated significant increased odds. CONCLUSION: The findings of this observational data suggest that GLP-1RAs do not increase the risk of most orofacial conditions and may be inversely associated with mucosal, neuropathic, salivary, and dental disorders. However, clinicians should monitor for GERD-related symptoms. Further prospective research is required to validate these associations. Copyright © 2026 Elsevier Inc. All rights reserved. Conflict of interest statement: DECLARATIONS OF INTEREST None.
Get the latest research news and industry updates sent to your inbox weekly. No spam, unsubscribe anytime.
For research purposes only. Unsubscribe anytime.